Table 4.
Acute gastrointestinal symptoms observed during the intervention period.
| Placebo (n = 30) | LF (n = 22) | p | |
|---|---|---|---|
| DIARRHEA | |||
| Prevalence, n (%) | 26 (86.7) | 19 (86.4) | 1.000 |
| Diarrhea days | 1.5 (1, 3.25) | 2 (1, 5.25) | 0.393 |
| Duration, days/episode | 1 (1, 2) | 1.8 (1, 3) | 0.417 |
| VOMITING | |||
| Prevalence, n (%) | 15 (50.0) | 12 (54.5) | 0.785 |
| Vomiting days | 0.5 (0, 1) | 1 (0, 1) | 0.778 |
| Duration, days/episode | 1 (1, 1.33) | 1 (1, 1.75) | 0.867 |
| FATIGUE | |||
| Prevalence, n (%) | 11 (36.7) | 11 (50.0) | 0.401 |
| Fatigue days | 0 (0, 1) | 0.5 (0, 1.25) | 0.406 |
| Duration, days/episode | 1 (1, 1.5) | 1 (1, 2) | 0.949 |
Values represent the number (%) or the median (interquartile range).
Prevalence is defined as the number of participants who experienced more than one symptom.
Symptom days are defined as the cumulative number of symptomatic days.
Duration is defined as the mean of consecutive days per episode.